Company insiders — CEOs, CFOs, directors and 10% owners — buying their own company's stock on the open market: every purchase of $250K or more from the previous day's Form 4 filings, largest first, with an AI summary of the day.
510,873 shares across 3 tranches at $32.28–$34.48 (wtd avg $33.43). Now $34.41 (+2.9% since buy). Strategic investor expanding position; Nippon Life has been a consistent accumulator since 2022.
718,750 shares at $16.00 (IPO price), Oct 16 trade date, via Ascenta Capital Fund I. Now $16.34 (+2.1% since buy). Purchased on IPO day alongside preferred-to-common conversions. Strong insider conviction at deal price.
194,228 shares across two days: 92,475 @ $12.5647 (Oct 15) + 101,753 @ $12.3870 (Oct 16). Now $12.25 (−1.8% since buy). Non-traded REIT; purchase via Bluerock Asset Management LLC (indirect). Routine management accumulation.
AIThe day in insider buying
SEC Form 4 Insider Scan — October 20, 2026
Scanned the last 24 hours of EDGAR Form 4 filings (Oct 19–20, 2026). 3 qualifying buys (≥ $250K, transaction type P) totalling $31.0M.
Headline filings
CRBG — Nippon Life Insurance Co (10% Owner) bought 510,873 shares ≈ $17.1M at $33.43 weighted avg; now $34.41 (+2.9% since buy). Large strategic holder continuing to build its position in Corebridge Financial — Nippon Life has been a consistent accumulator since its 2022 investment alongside AIG's restructuring. (filing)
IAM — Evan Lockwood Rachlin (Director) bought 718,750 shares ≈ $11.5M at $16.00 IPO price; now $16.34 (+2.1% since buy). Direct purchase at the Iambic Therapeutics IPO price, executed through Ascenta Capital Fund I on Oct 16 — same day the company's preferred stock converted to common. Strong conviction signal at deal price. (filing)
BPRE — Ramin Kamfar (Director) bought 194,228 shares ≈ $2.4M at $12.47 weighted avg; now $12.25 (−1.8% since buy). Bluerock Asset Management founder/CEO buying additional shares in the fund he manages across two days (Oct 15–16). (filing)
Notes
Themes: Institutional conviction (Nippon Life/CRBG) + biotech IPO directional bet (IAM) dominate the session. CRBG is the standout — a $17.1M add by a major strategic 10% holder at a ~2.9% premium suggests continued confidence in Corebridge's insurance run-off earnings power. IAM is a fresh IPO name; the director's $11.5M purchase at exactly the $16 offering price is a strong signal of insider alignment. BPRE is a non-traded REIT with thin secondary volume; Kamfar's purchase is routine but consistent with prior monthly adds. No cluster activity at any single operating company. October earnings season context: none of these three companies had recent major earnings releases within 5 days of the trade dates.
Source: insiders' SEC Form 4 filings — open-market purchases (transaction code P) of $250K or more filed in the previous day. Insiders must file within two business days of a trade, so a purchase can be a day or two older than its filing. Average price = value ÷ shares. Insiders buy for many reasons and a purchase is no guarantee the shares will rise. The summaries are written by AI as a research aid — not financial advice or a recommendation to buy or sell any security, and they can be wrong.
SPX Lens Insider Buying reads the SEC Form 4 filings insiders file after trading their own company's
stock and lists every open-market purchase of $250K or more — who bought, their role, how much and at what
average price. Insiders sell for many reasons, but they usually buy for one: they think the shares are worth more. It is free,
and a new scan is posted every trading day. How to read insider buying →
See where SPX is heading next. The SPX Lens chart shows key levels, live signals and an AI forecast for the next bars — free to try.